{"DataElement":{"publicId":"64565","version":"3","preferredName":"Reverse Transcriptase-Polymerase Chain Reaction Genetic Marker Assessment Type","preferredDefinition":"a description of a gene abnormality associated with cancer evaluated in a DNA sample by a technique which detects a defined genetic sequence by transcribing RNA strands into a DNA complement.","longName":"RT-PCR_GNMK_ASSES_TP","context":"CTEP","contextVersion":"2.31","DataElementConcept":{"publicId":"2010505","version":"3","preferredName":"Reverse Transcriptase-Polymerase Chain Reaction Genetic Marker Assessment","preferredDefinition":"related to the evaluation to identify genes associated with cancer using a technique to detect a defined genetic sequence in a DNA sample by transcribing RNA strands into a DNA complement.","longName":"RT-PCR_GENMKR_ASSESS","context":"CTEP","contextVersion":"2.31","ObjectClass":{"publicId":"2499420","version":"1","preferredName":"RT-PCR","preferredDefinition":"RT-PCR is short for reverse transcriptase-polymerase chain reaction. It is a technique in which an RNA strand is first transcribed into a DNA complement and then subjected to PCR amplification. Transcribing an RNA strand into a DNA complement is termed reverse transcription and is done by the enzyme reverse transcriptase. (from Wikipedia)","longName":"C18136","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Reverse Transcriptase-Polymerase Chain Reaction","conceptCode":"C18136","definition":"A laboratory procedure in which an RNA strand is first transcribed into a DNA complement and then subjected to PCR amplification. Transcribing an RNA strand into a DNA complement is termed reverse transcription and is done by the enzyme reverse transcriptase.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"197CA31B-7213-3AD2-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-07-26","endDate":null,"createdBy":"PWEST","dateCreated":"2006-07-26","modifiedBy":"ONEDATA","dateModified":"2006-07-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2497250","version":"1","preferredName":"Genetic Marker Assessment","preferredDefinition":"Alterations in DNA that may indicate an increased risk of developing a specific disease or disorder.:Examination of the body by auscultation, palpation, percussion, inspection, and olfaction.  (Taber's)","longName":"C16622:C20989","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Genetic Marker","conceptCode":"C16622","definition":"A segment of DNA with an identifiable physical location on a chromosome and whose inheritance can be followed.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Physical Examination","conceptCode":"C20989","definition":"A systemic evaluation of the body and its functions using visual inspection, palpation, percussion and auscultation. The purpose is to determine the presence or absence of physical signs of disease or abnormality for an individual's health assessment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"18F641F3-346C-6FBD-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-07-19","endDate":null,"createdBy":"PWEST","dateCreated":"2006-07-19","modifiedBy":"ONEDATA","dateModified":"2006-07-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008557","version":"1","preferredName":"Lab Results","preferredDefinition":"the results of laboratory tests.","longName":"LAB_RESULTS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B2CFBA7D-D009-7227-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-27","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-27","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"197E063B-F00E-3616-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-07-26","endDate":null,"createdBy":"PWEST","dateCreated":"2006-07-26","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":"updated for ISO compliance","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"2015495","version":"3","preferredName":"Reverse Transcriptase-Polymerase Chain Reaction Genetic Marker Assessment Type","preferredDefinition":"a description of a gene abnormality associated with cancer evaluated in a DNA sample by a technique which detects a defined genetic sequence by transcribing RNA strands into a DNA complement.","longName":"RT-PCR_GNMK_ASSES_TP","context":"CTEP","contextVersion":"2.31","type":"Enumerated","dataType":"CHARACTER","minLength":"1","maxLength":"40","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Other","valueDescription":"OTHER SPECIFY","ValueMeaning":{"publicId":"2559668","version":"1","preferredName":"OTHER SPECIFY","longName":"2559668","preferredDefinition":"Be specific about something; define clearly.: Different than the one(s) previously specified or mentioned.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Specify","conceptCode":"C25685","definition":"Be specific about something; define clearly.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B621-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"SOKKERL","dateModified":"2018-05-11","changeDescription":"Concept annotation added for UPitt/TCGA.  Ylu, 01/29/2015.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"197E063B-EFE6-3616-E044-0003BA3F9857","beginDate":"2002-02-11","endDate":null,"createdBy":"PWEST","dateCreated":"2006-07-26","modifiedBy":"PWEST","dateModified":"2006-07-26","deletedIndicator":"No"},{"value":"AML1/ETO","valueDescription":"AML1-ETO Fusion Protein Expression","ValueMeaning":{"publicId":"2580305","version":"1","preferredName":"AML1-ETO Fusion Protein Expression","longName":"2580305v1.00","preferredDefinition":"Expression of a fusion protein that results from a t(8;21)(q22;q22) translocation, which involves the human genes RUNX1 and RUNX1T1 and is associated with acute myeloid leukemia.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"AML1-ETO Fusion Protein Expression","conceptCode":"C37218","definition":"Expression of a fusion protein that results from a t(8;21)(q22;q22) translocation, which involves the human genes RUNX1 and RUNX1T1 and is associated with acute myeloid leukemia.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-06BE-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-07-26","endDate":null,"createdBy":"PWEST","dateCreated":"2006-07-26","modifiedBy":"KUMMEROA","dateModified":"2023-09-01","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"198337A5-2090-5D74-E044-0003BA3F9857","beginDate":"2006-07-26","endDate":null,"createdBy":"PWEST","dateCreated":"2006-07-26","modifiedBy":"PWEST","dateModified":"2006-07-27","deletedIndicator":"No"},{"value":"BCR/ABL","valueDescription":"BCR-ABL1 Fusion Protein Expression","ValueMeaning":{"publicId":"2580306","version":"1","preferredName":"BCR-ABL1 Fusion Protein Expression","longName":"2580306v1.00","preferredDefinition":"Bcr/abl is the gene rearrangement that is associated primarily with the disease chronic myelogenous leukemia and less frequently with acute lymphoblastic leukemia.  This rearrangement results in the formation of the BCR-ABL1 fusion protein.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"BCR-ABL1 Fusion Protein Expression","conceptCode":"C36715","definition":"Bcr/abl is the gene rearrangement that is associated primarily with the disease chronic myelogenous leukemia and less frequently with acute lymphoblastic leukemia.  This rearrangement results in the formation of the BCR-ABL1 fusion protein.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-06BF-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-07-26","endDate":null,"createdBy":"PWEST","dateCreated":"2006-07-26","modifiedBy":"KUMMEROA","dateModified":"2023-09-01","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"198337A5-20A8-5D74-E044-0003BA3F9857","beginDate":"2006-07-26","endDate":null,"createdBy":"PWEST","dateCreated":"2006-07-26","modifiedBy":"PWEST","dateModified":"2006-07-27","deletedIndicator":"No"},{"value":"BCR/ABL-p190","valueDescription":"p190 Fusion Protein Expression","ValueMeaning":{"publicId":"2580307","version":"1","preferredName":"p190 Fusion Protein Expression","longName":"2580307v1.00","preferredDefinition":"Expression of a fusion protein with an apparent molecular weight of 190 kilodaltons that results from a fusion of the human genes BCR and ABL1.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"p190 Fusion Protein Expression","conceptCode":"C36714","definition":"Expression of a fusion protein with an apparent molecular weight of 190 kilodaltons that results from a fusion of the human genes BCR and ABL1.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-06C0-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-07-26","endDate":null,"createdBy":"PWEST","dateCreated":"2006-07-26","modifiedBy":"KUMMEROA","dateModified":"2023-09-01","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"198337A5-20C0-5D74-E044-0003BA3F9857","beginDate":"2006-07-26","endDate":null,"createdBy":"PWEST","dateCreated":"2006-07-26","modifiedBy":"PWEST","dateModified":"2006-07-27","deletedIndicator":"No"},{"value":"BCR/ABL-p210","valueDescription":"p210 Fusion Protein Expression","ValueMeaning":{"publicId":"2580308","version":"1","preferredName":"p210 Fusion Protein Expression","longName":"2580308v1.00","preferredDefinition":"Expression of a fusion protein with an apparent molecular weight of 210 kilodaltons that results from a fusion of the human genes BCR and ABL1.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"p210 Fusion Protein Expression","conceptCode":"C36712","definition":"Expression of a fusion protein with an apparent molecular weight of 210 kilodaltons that results from a fusion of the human genes BCR and ABL1.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-06C1-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-07-26","endDate":null,"createdBy":"PWEST","dateCreated":"2006-07-26","modifiedBy":"KUMMEROA","dateModified":"2023-09-01","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"198337A5-20D8-5D74-E044-0003BA3F9857","beginDate":"2006-07-26","endDate":null,"createdBy":"PWEST","dateCreated":"2006-07-26","modifiedBy":"PWEST","dateModified":"2006-07-27","deletedIndicator":"No"},{"value":"BCR/ABL-p230","valueDescription":"p230 Fusion Protein Expression","ValueMeaning":{"publicId":"2580309","version":"1","preferredName":"p230 Fusion Protein Expression","longName":"2580309v1.00","preferredDefinition":"Expression of a fusion protein with an apparent molecular weight of 230 kilodaltons that results from a fusion of the human genes BCR and ABL1.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"p230 Fusion Protein Expression","conceptCode":"C36713","definition":"Expression of a fusion protein with an apparent molecular weight of 230 kilodaltons that results from a fusion of the human genes BCR and ABL1.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-06C2-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-07-26","endDate":null,"createdBy":"PWEST","dateCreated":"2006-07-26","modifiedBy":"KUMMEROA","dateModified":"2023-09-01","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"198337A5-20F0-5D74-E044-0003BA3F9857","beginDate":"2006-07-26","endDate":null,"createdBy":"PWEST","dateCreated":"2006-07-26","modifiedBy":"PWEST","dateModified":"2006-07-27","deletedIndicator":"No"},{"value":"TEL/AML1","valueDescription":"TEL-AML1 Fusion Protein Expression","ValueMeaning":{"publicId":"2580310","version":"1","preferredName":"TEL-AML1 Fusion Protein Expression","longName":"2580310v1.00","preferredDefinition":"Expression of a fusion protein containing the helix-loop-helix domain encoded by the human ETV6 gene and the DNA-binding and transactivation domains encoded by the human RUNX1 gene as a result of a t(12;21)(p13; q22) translocation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"ETV6-RUNX1 Fusion Protein Expression","conceptCode":"C37227","definition":"Expression of a fusion protein containing the helix-loop-helix domain encoded by the human ETV6 gene and the DNA-binding and transactivation domains encoded by the human RUNX1 gene as a result of a t(12;21)(p13; q22) translocation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-06C3-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-07-26","endDate":null,"createdBy":"PWEST","dateCreated":"2006-07-26","modifiedBy":"KUMMEROA","dateModified":"2023-09-01","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"198337A5-2108-5D74-E044-0003BA3F9857","beginDate":"2006-07-26","endDate":null,"createdBy":"PWEST","dateCreated":"2006-07-26","modifiedBy":"PWEST","dateModified":"2006-07-27","deletedIndicator":"No"},{"value":"PML/RAR-alpha","valueDescription":"PML-RARalpha Fusion Protein Expression","ValueMeaning":{"publicId":"2580311","version":"1","preferredName":"PML-RARalpha Fusion Protein Expression","longName":"2580311v1.00","preferredDefinition":"Expression of a fusion protein that results from a fusion of the human genes PML and RARA.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"PML-RARA Fusion Protein Expression","conceptCode":"C37223","definition":"Expression of a fusion protein that results from a fusion of the human genes PML and RARA.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-06C4-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-07-26","endDate":null,"createdBy":"PWEST","dateCreated":"2006-07-26","modifiedBy":"KUMMEROA","dateModified":"2023-09-01","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"198337A5-2120-5D74-E044-0003BA3F9857","beginDate":"2006-07-26","endDate":null,"createdBy":"PWEST","dateCreated":"2006-07-26","modifiedBy":"PWEST","dateModified":"2006-07-27","deletedIndicator":"No"},{"value":"PLZF/RAR-alpha","valueDescription":"PLZF-RARalpha Fusion Protein Expression","ValueMeaning":{"publicId":"2580312","version":"1","preferredName":"PLZF-RARalpha Fusion Protein Expression","longName":"2580312v1.00","preferredDefinition":"A fusion protein encoded by a t(15;17) translocation, which involves the human genes ZBTB16 and RARA and is characteristic of acute promyelocytic leukemia. It is a transcriptional repressor with both gain-of-function and dominant-negative properties, resulting in transcriptional repression of retinoic acid and non-retinoic acid target genes and culminating in differentiation arrest.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"ZBTB16-RARA Fusion Protein Expression","conceptCode":"C37220","definition":"A fusion protein encoded by a t(15;17) translocation, which involves the human genes ZBTB16 and RARA and is characteristic of acute promyelocytic leukemia. It is a transcriptional repressor with both gain-of-function and dominant-negative properties, resulting in transcriptional repression of retinoic acid and non-retinoic acid target genes and culminating in differentiation arrest.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-06C5-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-07-26","endDate":null,"createdBy":"PWEST","dateCreated":"2006-07-26","modifiedBy":"KUMMEROA","dateModified":"2023-09-01","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"198337A5-2138-5D74-E044-0003BA3F9857","beginDate":"2006-07-26","endDate":null,"createdBy":"PWEST","dateCreated":"2006-07-26","modifiedBy":"PWEST","dateModified":"2006-07-27","deletedIndicator":"No"},{"value":"E2A/PBX1","valueDescription":"E2A-PBX1 Fusion Protein Expression","ValueMeaning":{"publicId":"2580313","version":"1","preferredName":"E2A-PBX1 Fusion Protein Expression","longName":"2580313v1.00","preferredDefinition":"Expression of a fusion protein that results from a t(1;19)(q23;p13) translocation, which involves the human genes E2A and PBX1 and is associated with B lymphoblastic leukemias.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"TCF3-PBX1 Fusion Protein Expression","conceptCode":"C37226","definition":"Expression of a fusion protein that results from a t(1;19)(q23;p13) translocation, which involves the human genes E2A and PBX1 and is associated with B lymphoblastic leukemias.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-06C6-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-07-26","endDate":null,"createdBy":"PWEST","dateCreated":"2006-07-26","modifiedBy":"KUMMEROA","dateModified":"2023-09-01","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"198337A5-2150-5D74-E044-0003BA3F9857","beginDate":"2006-07-26","endDate":null,"createdBy":"PWEST","dateCreated":"2006-07-26","modifiedBy":"PWEST","dateModified":"2006-07-27","deletedIndicator":"No"},{"value":"AML1/EVI1","valueDescription":"EVI1-AML1 Fusion Protein Expression","ValueMeaning":{"publicId":"2580314","version":"1","preferredName":"EVI1-AML1 Fusion Protein Expression","longName":"2580314v1.00","preferredDefinition":"Expression of a fusion protein that results from a t(3;21)(q26;q22) translocation, which involves the human genes MECOM and RUNX1 and is associated with chronic myelogenous leukemia.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"MECOM-RUNX1 Fusion Protein Expression","conceptCode":"C41074","definition":"Expression of a fusion protein that results from a t(3;21)(q26;q22) translocation, which involves the human genes MECOM and RUNX1 and is associated with chronic myelogenous leukemia.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-06C7-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-07-26","endDate":null,"createdBy":"PWEST","dateCreated":"2006-07-26","modifiedBy":"KUMMEROA","dateModified":"2023-09-01","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"198337A5-2168-5D74-E044-0003BA3F9857","beginDate":"2006-07-26","endDate":null,"createdBy":"PWEST","dateCreated":"2006-07-26","modifiedBy":"PWEST","dateModified":"2006-07-27","deletedIndicator":"No"},{"value":"MLL/AF4","valueDescription":"MLL-AF4 Fusion Protein Expression","ValueMeaning":{"publicId":"2580315","version":"1","preferredName":"MLL-AF4 Fusion Protein Expression","longName":"2580315v1.00","preferredDefinition":"Expression of a fusion protein that results from the insertion mutation ins(5;11)(q31;q13q23), which involves the human genes KMT2A and AFF1 and is associated with acute lymphoblastic leukemia.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"KMT2A-AFF1 Fusion Protein Expression","conceptCode":"C37228","definition":"Expression of a fusion protein that results from the insertion mutation ins(5;11)(q31;q13q23), which involves the human genes KMT2A and AFF1 and is associated with acute lymphoblastic leukemia.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-06C8-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-07-26","endDate":null,"createdBy":"PWEST","dateCreated":"2006-07-26","modifiedBy":"KUMMEROA","dateModified":"2023-09-01","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"198337A5-2180-5D74-E044-0003BA3F9857","beginDate":"2006-07-26","endDate":null,"createdBy":"PWEST","dateCreated":"2006-07-26","modifiedBy":"PWEST","dateModified":"2006-07-27","deletedIndicator":"No"},{"value":"MLL/AF9","valueDescription":"MLL-AF9 Fusion Protein Expression","ValueMeaning":{"publicId":"2580316","version":"1","preferredName":"MLL-AF9 Fusion Protein Expression","longName":"2580316v1.00","preferredDefinition":"Expression of a fusion protein that results from a t(9;11)(p22;q23) translocation, which involves the human genes KMT2A and MLLT3 and is associated with many leukemias.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"MLLT3-KMT2A Fusion Protein Expression","conceptCode":"C38390","definition":"Expression of a fusion protein that results from a t(9;11)(p22;q23) translocation, which involves the human genes KMT2A and MLLT3 and is associated with many leukemias.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-06C9-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-07-26","endDate":null,"createdBy":"PWEST","dateCreated":"2006-07-26","modifiedBy":"KUMMEROA","dateModified":"2023-09-01","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"198337A5-2198-5D74-E044-0003BA3F9857","beginDate":"2006-07-26","endDate":null,"createdBy":"PWEST","dateCreated":"2006-07-26","modifiedBy":"PWEST","dateModified":"2006-07-27","deletedIndicator":"No"},{"value":"CBF-beta/MYH11","valueDescription":"CBFbeta-MYH11 Fusion Protein Expression","ValueMeaning":{"publicId":"2580317","version":"1","preferredName":"CBFbeta-MYH11 Fusion Protein Expression","longName":"2580317v1.00","preferredDefinition":"Expression of a fusion protein that results from an inversion or translocation, which involves the human genes CBFB and MYH11 and is associated with acute myeloid leukemias.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"CBFB-MYH11 Fusion Protein Expression","conceptCode":"C37219","definition":"Expression of a fusion protein that results from an inversion or translocation, which involves the human genes CBFB and MYH11 and is associated with acute myeloid leukemias.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-06CA-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-07-26","endDate":null,"createdBy":"PWEST","dateCreated":"2006-07-26","modifiedBy":"KUMMEROA","dateModified":"2023-09-01","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"198337A5-21B0-5D74-E044-0003BA3F9857","beginDate":"2006-07-26","endDate":null,"createdBy":"PWEST","dateCreated":"2006-07-26","modifiedBy":"PWEST","dateModified":"2006-07-27","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008557","version":"1","preferredName":"Lab Results","preferredDefinition":"the results of laboratory tests.","longName":"LAB_RESULTS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B2CFBA7D-D009-7227-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-27","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-27","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2234813","version":"1","preferredName":"Type","preferredDefinition":"Type; a subdivision of a particular kind of thing.","longName":"C25284","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"F970CDF6-F90E-21D3-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-14","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-06-14","modifiedBy":"SBR","dateModified":"2005-09-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"CTEP CDE Committee","workflowStatus":"RELEASED","registrationStatus":"Application","id":"197E063B-EF8C-3616-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-07-26","endDate":null,"createdBy":"PWEST","dateCreated":"2006-07-26","modifiedBy":"KUMMEROA","dateModified":"2023-09-01","changeDescription":"updated for ISO compliance","administrativeNotes":"2023.9.1 Updated PV def for 'No Value Exists'. ak","unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2008587","version":"2","longName":"Type of Disease","context":"CTEP","ClassificationSchemeItems":[{"publicId":"2811909","version":"1","longName":"Leukemia","context":"CTEP"}]},{"publicId":"2008589","version":"2","longName":"Type of Category","context":"CTEP","ClassificationSchemeItems":[{"publicId":"2811958","version":"1","longName":"Molecular Analysis","context":"CTEP"}]},{"publicId":"2008594","version":"2.31","longName":"Trial Type Usages (CDE Disease Committees)","context":"CTEP","ClassificationSchemeItems":[{"publicId":"2811935","version":"1","longName":"Pathology Leukemia","context":"CTEP"}]}],"AlternateNames":[],"ReferenceDocuments":[{"name":"Chimeric Gene","type":"Preferred Question Text","description":"Chimeric Gene","url":null,"context":"CTEP"},{"name":"CRF Text","type":"Alternate Question Text","description":"RT-PCR Marker Type","url":null,"context":"CTEP"}],"origin":"CTEP CDE Committee","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"197E063B-EF4A-3616-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-07-26","endDate":null,"createdBy":"PWEST","dateCreated":"2006-07-26","modifiedBy":"REEVESD","dateModified":"2011-04-05","changeDescription":"updated for ISO compliance","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}